AILNH

Aileron Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class medicines for orphan pulmonary and fibrosis diseases. Following its 2023 merger with Lung Therapeutics, the company shifted its strategic focus to respiratory conditions, led by its candidate LPT-023, an inhaled Tie2 activator for idiopathic pulmonary fibrosis. The company's pipeline also includes treatments for pleural effusions and other fibrotic disorders, leveraging expertise in inhaled drug delivery and peptide chemistry. Aileron is headquartered in Austin, Texas, and is dedicated to addressing high unmet needs in lung health through innovative therapeutic modalities.